Hennion & Walsh Asset Management Inc. Purchases 96,177 Shares of Indivior PLC $INDV

Hennion & Walsh Asset Management Inc. increased its position in Indivior PLC (NASDAQ:INDV) by 43.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 317,600 shares of the company’s stock after buying an additional 96,177 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.25% of Indivior worth $11,395,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in INDV. GAMMA Investing LLC grew its position in Indivior by 544.6% in the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after acquiring an additional 1,013 shares in the last quarter. CWM LLC bought a new position in shares of Indivior during the 3rd quarter valued at $25,000. Quarry LP bought a new position in shares of Indivior during the 3rd quarter valued at $26,000. Raymond James Financial Inc. acquired a new stake in shares of Indivior in the 2nd quarter valued at $26,000. Finally, Campbell & CO Investment Adviser LLC lifted its stake in shares of Indivior by 3.5% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 53,782 shares of the company’s stock valued at $1,297,000 after purchasing an additional 1,834 shares during the last quarter. Institutional investors own 60.33% of the company’s stock.

Insider Buying and Selling

In other Indivior news, Director Daniel A. Ninivaggi acquired 775 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the purchase, the director owned 16,923 shares of the company’s stock, valued at approximately $598,904.97. This trade represents a 4.80% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Mark Stejbach acquired 775 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, with a total value of $27,427.25. Following the transaction, the director directly owned 16,847 shares in the company, valued at $596,215.33. The trade was a 4.82% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 5,842 shares of company stock valued at $203,342 in the last quarter.

Analysts Set New Price Targets

Several equities analysts have commented on INDV shares. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 price target on shares of Indivior in a research report on Wednesday, December 3rd. HC Wainwright upped their price target on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Northland Securities set a $50.00 price objective on Indivior in a report on Tuesday, January 20th. Finally, Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Indivior currently has an average rating of “Buy” and an average target price of $39.33.

Indivior Stock Performance

NASDAQ INDV opened at $28.97 on Monday. Indivior PLC has a 1 year low of $8.64 and a 1 year high of $38.00. The company has a fifty day simple moving average of $32.80 and a 200 day simple moving average of $31.05. The company has a market cap of $3.62 billion, a P/E ratio of 17.66 and a beta of 0.83.

Indivior (NASDAQ:INDV) last announced its earnings results on Friday, February 27th. The company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.65 by $0.17. The firm had revenue of $358.00 million for the quarter, compared to the consensus estimate of $305.62 million. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. Equities research analysts forecast that Indivior PLC will post 1.22 EPS for the current fiscal year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.